World Antibody Drug Conjugates Market 2015-2025 - The Market is Being Driven by the Sales of ADCETRIS® and KADCYLA®

Dublin, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/f7m9sb/antibody_drug) has announced the addition of the "Antibody Drug Conjugates Market (3rd Edition)" report to their offering.

The Antibody Drug Conjugates Market (3rd edition), 2015-2025 report provides a comprehensive analysis of the current market landscape and future outlook of the growing pipeline of ADCs. The ADC market has been one of the most actively evolving markets over the last few years and encompasses a myriad of therapies that can be potentially exploited for a broad range of cancer indications.

The ADC market is being driven by the sales of ADCETRIS® and KADCYLA®, the only two commercially available drugs. It is a relatively new concept with respect to technology, although the individual molecules that form ADCs have been used since long. This new class of therapeutics has witnessed a strong acceptance from both big and small pharmaceutical companies as they try to fill gaps in their respective oncology pipelines.

One of the key objectives of the study is to review and quantify the opportunities laid by the robust, opportunistic and broad pipelines of the pharmaceutical firms. With two marketed drugs (ADCETRIS® and KADCYLA®), the market is treading its way towards fulfilling a huge untapped promise.

Owing to niche nature of the market, with most products in the pipeline, we have provided three market forecast scenarios to add robustness to our model. The conservative, base and optimistic scenarios represent three different tracks of industry's evolution. All actual figures have been sourced and analysed from publicly available information. The figures mentioned in this report are in USD, unless otherwise specified.

Amongst other elements, the report elaborates on the following key areas:

- The current state of the market with respect to key players, developmental stage of pipeline products (both clinical / pre-clinical) and indications targeted
- Technology providers, and key cytotoxin, linker and conjugation technologies supporting the development of improved ADCs
- Recent partnerships that have taken place over the last decade including product co-development, licensing and clinical trial collaborations
- Various investments and grants received by the companies focused in this area
- Therapeutic areas forming the current focus of developers, the gradual drift and expansion towards broader application areas
- Competitive landscape and inherent threats to growth in the short and long term
- Development and sales potential, based on target consumer segments, likely adoption rate and expected pricing, of molecules in late stages of development

The base year for the report is 2015. The report provides market forecast for the period 2015-2025. The research, analysis and insights presented in this report include potential sales of several ADCs; this analysis is backed by a deep understanding of key drivers behind the growth.

Example Highlights

- Driven by the sales of ADCETRIS® and KADCYLA® (the only two drugs currently available commercially), the ADC market is estimated to be worth around USD 0.9 billion in 2015.
- The market has a strong clinical pipeline of 53 molecules; nearly one-third of the molecules are in Phase II or Phase III of development. The dynamic pipeline also includes a number of molecules in preclinical/ discovery stage; in our research, we came across over 60 such molecules.
- Most commonly used cytotoxins for ADCs under clinical development include auristatin, calicheamicin, maytansine and duocarmycin. Auristatin dominates the market and accounts for over 50% of ADCs in clinical development.
- Roche, with six molecules in clinical development, has the most developed pipeline of ADCs. Other established players in the market are (in alphabetical order) AbbVie, Amgen, Astellas, AstraZeneca, Bayer, BMS, GSK, Novartis, Pfizer and Sanofi.
- Relative new entrants include (in alphabetical order) AbGenomics, Allozyne, Ambrx, Biotest, Celldex Therapeutics, Centrose, CytomX Therapeutics, Esperance Pharmaceuticals, Formation Biologics, Genmab, Heidelberg Pharma, Igenica, Immunomedics, Oxford BioTherapeutics, Kairos Therapeutics, Merrimack Pharmaceuticals, Mersana Therapeutics, NBE Therapeutics, Philochem, PhotoBiotics, Progenics Pharmaceuticals, Sorrento Therapeutics, Stem CentRx, Sutro Biopharma, Synthon, Zymeworks; emergence of these firms is likely to provide the necessary push, both in terms of technology and innovation.
- About 70%-80% of ADC manufacturing is currently outsourced. There are limited number of contract manufacturers with capabilities for development of linkers and cytotoxins. In addition, even fewer CMOs provide conjugation services for ADC.
- Several technological developments have taken place in the recent past; more stable linkers and potent cytotoxins are likely to ensure that the next generation ADCs have improved safety/efficacy profile.
- With around 10 new ADC commercial launches over the coming decade, we believe the overall market will be worth USD 10 billion annually by 2025.Favourable market environment and regulatory regimes could result in an even steeper growth.

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Market Overview

5. KOL Analysis

6. Key Therapeutic Areas For ADCS

7. Upcoming ADC Drugs: Detailed Profiles And Market Forecast

8. Partnerships And Collaborations

9. Venture Capital Interest

10. Company Profiles

Companies Include:

- 5AM Ventures
- AAIPharma Services Corp
- AB SCIEX
- ACES Pharma
- ADC Therapeutics
- AIDS Malignancy Consortium
- ALMAC Group
- AMRI Global
- ARCH Venture Partners
- AbGenomics
- AbbVie
- Abramson Cancer Center of the University of Pennsylvania
- Abraxis BioScience
- Academic Medical Center, University of Amsterdam
- Academic and Community Cancer Research United
- Adimab
- Advanced Biotechnologies Venture Fund
- Advantage Capital Partners
- Advent Venture Partners
- Affinity Lifesciences
- Agensys
- Alexandria Real Estate Equities
- Algeta
- Allos Therapeutics
- Allozyne
- Alta Partners
- Ambrx
- American Cancer Society
- American Society of Clinical Oncology (ASCO)
- American Society of Haematology, San Francisco
- AmerisourceBergen Corporation
- Amgen
- Amgen Ventures
- Apax Partner
- Apposite Capital
- Aravis Ventures
- Asan Medical Center
- Aspyrian Therapeutics
- Astellas Pharma
- AstraZeneca
- Asymchem
- Auven Therapeutics
- Avid Biologics
- BSI
- BSP Pharmaceuticals
- Bachem
- BankInvest Group
- Barbara Ann Karmanos Cancer Institute
- Baxter BioPharma Solutions
- Bayer Healthcare
- Bear Sterns Health Innoventures
- Beatson West of Scotland Cancer Center
- BioAgilytix Labs
- BioOutsource
- BioPharma Solutions
- BioWa
- Biogen Idec
- Biotechnique
- Biotecnol
- Biotest
- Boehringer Ingelheim
- Boehringer Ingelheim Venture Fund
- Bristol-Myers Squibb
- Brown University
- CARBOGEN AMCIS
- CMC Biologics
- CTI Life Sciences Fund
- Cambrex Corporation
- Canaan Partners
- Cancer Institute of Lorraine
- Cancer Research Technology (CRT), UK
- Cancer Research, UK
- Cancer Treatment Centers of America
- Cantonal Hospital of St. Gallen
- Cardinal Health
- Carnegie Kapitalforvaltning
- Cascade Investment
- Casdin Capital
- Catalent Pharma Solution
- Catapult Ventures
- Celgene
- Celldex Therapeutics
- Centers for Disease Control and Prevention
- Centre Hospitalier Lyon Sud, France
- Centre Oscar Lambret
- Centrose
- ChemCon
- ChemPartner
- Children's Oncology Group
- Chu de Limoges
- Chugai Pharmaceutical
- City of Hope Medical Center
- Coldstream Laboratories
- Columbia University
- Concortis
- Cooley Godward Kronish
- Cormorant Asset Management
- Creative Biolabs
- Credit Suisse First Boston Next Fund
- Crocker Ventures
- CuraGen
- Cytogen Corporation
- CytomX Therapeutics
- Cytovance Biologics LLC
- Daiichi Sankyo
- Dalton Pharma Services
- Dana-Farber Cancer Institute
- Dansk Erhvervsinvestering
- Deerfield Management
- Dendreon Corporation
- Dishman Group
- Dow Venture Capital
- Duquesne Capital Management
- ECOG-ACRIN Cancer Research Group
- EirGenix
- Eisai
- Elder Pharmaceuticals
- Eli Lilly
- Endo Pharmaceuticals
- Endocyte
- Esperance Pharmaceuticals
- Eucodis
- European Organisation for Research and Treatment of Cancer
- Evonik
- Expansion Venture Capital
- FUJIFILM Diosynth Biotechnologies
- Ferring Pharmaceuticals
- Ferro Pfanstiehl
- Fidelity Biosciences
- Fidelity Investments
- Formation Biologics
- Formosa Laboratories
- Fox Chase Cancer Center
- Fred Alger Management
- GLOBOCAN
- GSK
- GTC Biotherapeutics
- Genentech
- General Hospital Linz
- Genmab
- Genzyme
- German Federal Ministry of Education and Research
- Gilead Sciences
- Glynn Capital Management
- Goodwin Biotechnology
- Guys Hospital
- H&Q Life Sciences Investments
- H. Lee Moffitt Cancer Center & Research Institute Dept of Onc
- HBM BioVentures
- HBM Partners
- HNI Holdings
- Hambrecht & Quist Capital Management
- Harris and Harris Group
- Hartmann Oncology Radiotherapy Group
- HealthCap Venture Capital
- Heidelberg Pharma
- Heraeus
- Hercules Technology Growth Capital
- Hospital Ramon y Cajal, Madrid, Spain
- Hospital Saint-Louis
- Hospital Universitario de Salamanca
- ICM
- IDT Australia
- INC Research
- IRCCS AOU San Martino
- IUHealth Goshen Center for Cancer Care
- Igenica
- ImClone Systems
- Immunogen
- Immunomedics
- Index Ventures
- Innovis Investments
- Innsbruck Medical University
- Institut Bergonié, Bordeaux
- Institut Curie
- International Biotechnology Trust
- Invenra
- Iroquois Capital Group
- JAFCO
- Janssen Biotech
- Jennison Associates
- Johnson & Johnson
- Jules Bordet Institute
- Kairos Therapeutics
- Karolinska university hospital
- Kemwell
- Korea Cancer Center Hospital
- LODH Private Equity Partners
- Leica Biosystems
- Leukaemia and Lymphoma Society
- Life Science Pharmaceuticals
- Ligand Pharmaceuticals
- Lilly Ventures
- Lombard Odier Darier Hentsch & Cie
- Lonza
- Lymphoma Study Association
- M D Anderson Cancer Center
- MAB Discovery
- MPM Capital
- MS Seed Capital
- MS Ventures
- MacroGenics
- Massachusetts General Hospital
- Maverick Capital
- Mayo Clinic
- McKesson Corporation
- MedImmune
- MedStar Washington Hospital Center
- Medarex
- Medical College of Wisconsin
- Medical University of Vienna
- Medivation
- Memorial Sloan-Kettering Cancer Center
- Menarini
- Merck
- Merrimack Pharmaceuticals
- Mersana Therapeutics
- MiMabs
- Millenium Pharmaceuticals
- Modal Capital L.P.
- Molecular Insight Pharmaceuticals
- Morphotek
- NBE Therapeutics
- NSABP Foundation
- Natco Pharma
- National Cancer Center of Korea
- National Cancer Institute
- National Research Council of Canada
- New Enterprise Associates
- New York Medical College
- Nextech Venture
- Noonday Asset Management
- Nordic Nanovector
- Norfolk and Norwich Hospital
- Northwestern University
- Nottingham University Hospitals NHS Trust
- Novartis
- Novasep
- Novella Clinical
- OVP Venture Partners
- Ohio State University
- Oncology Institute of Southern Switzerland
- Oncology-Rinat Research and Development (ORRD)
- Ono Pharmaceutical
- Onyx Pharmaceuticals
- Orbimed Advisors
- Oslo University Hospital
- Oxford BioTherapeutics
- Oxford Capital Partners
- Pacific GMP
- Patheon
- Perceptive Advisors
- Pfizer
- Pfizer Venture Investments
- Pharmacyclics
- Philochem
- Philogen
- PhotoBiotics
- Pierre Fabre Group
- Piramal Pharma Solutions
- PolyTherics
- Presidio Partners
- Princess Margaret Hospital
- ProQuest Investments
- Progenics Pharmaceuticals
- Project Pharmaceutics
- PureTech Ventures
- QPS Holdings
- Quanta BioDesign
- Queen Elizabeth Hospital
- Recepta Biopharma
- Redmile Group
- Redwood Bioscience
- Regional Center for the Fight Against Cancer
- ReqMed Company
- Research Corporation Technologies
- Roche
- Roche Venture Fund
- Royal Liverpool Hospital
- S. Orsola Malpighi
- SAFC
- SCRI Innovations
- SV Life Sciences
- SafeBridge Consultants
- Sandoz
- Sanofi
- Sarah Cannon Research Institute
- Scale Venture Partners
- Scottish Widows Investment Partnership
- Seattle Genetics
- Seoul National University Hospital
- Seragon Pharmaceuticals
- Severance Hospital
- Shanghai Fosun Pharma
- Sigma-Aldrich Corporation
- Silicon Valley Bank
- Skyline Ventures
- Societa Italiana Corticosteroidi
- Society for Neuro-Oncology (SNO), Miami
- Sofinnova Ventures
- Sorenson Development
- Sorrento Therapeutics
- South East Growth Fund & Management
- Southampton General Hospital
- Southwest Oncology Group
- Spectrum Pharmaceuticals
- Spirogen
- St James University Hospital
- St. Jude Children's Research Hospital
- Stem CentRx
- Suez Ventures
- Sutro Biopharma
- Symbiosis Pharmaceutical Services
- Syntarga
- Synthon
- TPG-Axon Capital
- TUBE Pharma
- Takeda Pharmaceutical
- Tavistock Life Sciences
- Tekla Healthcare investors & Tekla Life Science Investors
- The Chemistry Research Solution
- The Christie Hospital
- The Churchill Hospital,UK
- The Column Group
- The Freeman Hospital
- The Institute of Haematology in Bologna
- The Methodist Hospital System
- Themelios Ventures
- Third Rock Ventures
- Tuas Biomedical Park
- Twilight Venture Partners
- UCB Pharma
- UCL School of Pharmacy
- UCLA Jonsson Comprehensive Cancer Center
- UT Southwestern Medical Center
- UZ Leuven Hospital
- Unilever Technology Ventures Fund B.V.
- Union Carbide Employees Pension Plan
- Union Chimique Belge
- University Hospital of Wales
- University Hospital, UK
- University Hospitals Seidman Cancer Center
- University of Alabama
- University of Amsterdam
- University of California
- University of Cologne
- University of Kansas Medical Center Research Institute
- University of Modena and Reggio Emilia
- University of Munich
- University of Oklahoma Stephenson Cancer Center
- University of Texas Health Science Center
- University of Ulm
- University of Washington Cancer Consortium
- VLG Investments
- Valeant Pharmaceutical
- Vanderbilt-Ingram Cancer Center
- Venrock Healthcare Capital Partners
- Ventana Medical Systems
- Venture Associates
- Ventures West Capital
- Versant Ventures
- Victor Hugo Surgical Clinic
- Virginia Cancer Specialists, PC
- VivaMab
- Vulcan Capital
- WILEX
- WT Investment Advisors Fund
- Washington University School of Medicine
- Waters
- Watson Pharmaceuticals
- Weill Medical College of Cornell University
- Wellington Management Company
- Western Regional Medical Center
- Wharton Biotechnology Partners
- WuXi PharmaTech
- Wyeth
- Zhejiang Medicine Co. (ZMC)
- Ziff Asset Management
- Zroche Venture Fund
- Zymework
- iBIOSOURCE

For more information visit http://www.researchandmarkets.com/research/f7m9sb/antibody_drug

                    
                    
                    CONTACT: Research and Markets
                             Laura Wood, Senior Manager
                             press@researchandmarkets.com
                    
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                    
                             U.S. Fax: 646-607-1907
                             Fax (outside U.S.): +353-1-481-1716
                    
                             Sector: Pharmaceuticals